Related Experiment Video
Updated: Jul 6, 2026
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver
Sonsawan Sangprasert1, Ratchaneewan Kwancharoen2, Witchakorn Ruamtawee3
1Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Dusit, Bangkok, Thailand.
Plos One
|December 3, 2025
Summary
Lifestyle changes significantly reduce liver fat in metabolic-associated steatotic liver disease (MASLD). Baseline metabolic factors, not just weight loss, predict liver fat reduction effectiveness.
Area of Science:
- Hepatology
- Metabolic Diseases
- Clinical Research
Background:
- Metabolic-associated steatotic liver disease (MASLD) is a growing global health concern.
- Understanding factors influencing liver fat reduction is crucial for effective management.
- Quantitative impact of baseline metabolic characteristics on MASLD treatment response remains unclear.
Purpose of the Study:
- To analyze the relationship between baseline factors and changes in controlled attenuation parameter (CAP) over 6 months.
- To compare the mean difference in CAP changes among individuals with MASLD.
- To identify predictors of liver fat reduction in MASLD patients undergoing lifestyle modification.
Main Methods:
- Cohort study of MASLD patients with hepatic steatosis (CAP ≥ 215 dB/m) and metabolic risk.
- Data collected: baseline characteristics, diet, exercise, and CAP measurements over 6 months.
- Multivariable regression models used to assess the impact of baseline factors on CAP change.
Main Results:
- Older age (≥45 years), higher waist circumference, and lower BMI were associated with greater CAP reduction.
- Presence of diabetes and better glycemic control also correlated with significant liver fat reduction.
- Baseline metabolic profile significantly influenced the extent of liver fat decrease.
Conclusions:
- Lifestyle modification effectively reduces liver fat in MASLD patients.
- Individualized metabolic profiles, rather than weight loss alone, dictate treatment response.
- Tailored lifestyle strategies are recommended for optimal MASLD management.
Related Concept Videos
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...